You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsosorbide Dinitrate
Accession NumberDB00883  (APRD00455)
TypeSmall Molecule
GroupsApproved
DescriptionA vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. [PubChem]
Structure
Thumb
Synonyms
1,4:3,6-Dianhydrosorbitol 2,5-dinitrate
Carvasin
Cedocard retard
D-Isosorbide dinitrate
Dianhydrosorbitol 2,5-dinitrate
Dinitrate d'isosorbide
Dinitrato de isosorbida
Dinitroisosorbide
Dinitrosorbide
Flindix
ISDN
Isoket
Isorbid
Isordil
Isosorbide 2,5-dinitrate
Isosorbide dinitrate
Isosorbidi dinitras
Nitrosorbide
Sorbide nitrate
Sorbidilat
Sorbidnitrate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cedocard-SR Srt 20mgtablet (extended-release)20 mgoralPaladin Labs Inc1987-12-312009-08-07Canada
Cedocard-SR Srt 40mgtablet (extended-release)40 mgoralPaladin Labs Inc1995-12-312009-08-07Canada
Coradur Tab 20mgtablet (extended-release)20 mgoralGlaxo Canada Inc1987-12-311997-04-25Canada
Coronextablet10 mgoralWyeth Canada1994-12-312007-01-08Canada
Coronextablet30 mgoralWyeth Canada1994-12-312007-01-08Canada
Coronex 5mg Sublingual Tabletstablet5 mgsublingualWyeth Canada1994-12-312007-01-08Canada
Dilatrate SRcapsule40 mg/1oralAuxilium Pharmaceuticals, Inc.2014-10-242015-12-29Us
Dilatrate SRcapsule, extended release40 mg/1oralActient Pharmaceuticals, LLC2012-02-15Not applicableUs
Isdntablet5 mgsublingualAa Pharma Inc1985-12-31Not applicableCanada
Isdntablet10 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Isdntablet30 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Isordil 10 Titradose Tab 10mgtablet10 mgoralWyeth Ltd.1960-12-311997-08-14Canada
Isordil 10 Titradose Tablets 10mgtablet10 mgoralWyeth Ayerst Canada Inc.1994-12-312002-06-10Canada
Isordil 30 Titradose Tab 30mgtablet30 mgoralWyeth Ltd.1974-12-311996-09-10Canada
Isordil 30 Titradose Tablets 30mgtablet30 mgoralWyeth Ayerst Canada Inc.1994-12-312001-08-30Canada
Isordil Sublingual Tab 5mgtablet5 mgsublingualWyeth Ltd.1967-12-311997-08-14Canada
Isordil Sublingual Tablets 5mgtablet5 mgsublingualWyeth Ayerst Canada Inc.1996-11-252001-08-30Canada
Isordil Titradosetablet5 mg/1oralValeant Pharmaceuticals North America LLC2013-04-01Not applicableUs
Isordil Titradosetablet40 mg/1oralBTA Pharmaceuticals, Inc.2009-10-012015-10-31Us
Isordil Titradosetablet40 mg/1oralValeant Pharmaceuticals North America LLC2013-04-01Not applicableUs
Isordil Titradosetablet40 mg/1oralAmerican Health Packaging2012-02-132015-12-29Us
Isordil Titradosetablet5 mg/1oralBTA Pharmaceuticals, Inc.2009-10-01Not applicableUs
Isosorbide 10 Tab 10mgtablet10 mgoralPro Doc Limitee1983-12-312010-07-13Canada
Isosorbide 30 Tab 30mgtablet30 mgoralPro Doc Limitee1983-12-312010-07-13Canada
Isosorbide Tab 30mgtablet30 mgoralPharmascience Inc1990-12-31Not applicableCanada
Isosorbide-5 Tab 5mgtablet5 mgsublingualPro Doc Limitee1986-12-312010-07-13Canada
Novo-sorbide Tab 10mgtablet10 mgoralNovopharm Limited1983-12-312012-10-22Canada
Novo-sorbide Tab 30mgtablet30 mgoralNovopharm Limited1983-12-312012-10-22Canada
Nu-isdn Tabletstablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-isdn Tabletstablet30 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-isdn Tabletstablet5 mgsublingualNu Pharm IncNot applicableNot applicableCanada
PMS-isosorbide Tab 10mgtablet10 mgoralPharmascience Inc1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isosorbidetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Isosorbidetablet30 mg/1oralGolden State Medical Supply, Inc.2007-01-10Not applicableUs
Isosorbidetablet10 mg/1oralCardinal Health1987-10-292015-12-29Us
Isosorbidetablet5 mg/1oralHikma Pharmaceutical1978-12-01Not applicableUs
Isosorbidetablet20 mg/1oralCardinal Health1987-10-292015-12-29Us
Isosorbidetablet10 mg/1oralGolden State Medical Supply, Inc.1987-10-26Not applicableUs
Isosorbidetablet10 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Isosorbidetablet10 mg/1oralHikma Pharmaceutical1978-12-01Not applicableUs
Isosorbidetablet20 mg/1oralGolden State Medical Supply, Inc.1987-11-02Not applicableUs
Isosorbidetablet20 mg/1oralMc Kesson Contract Packaging2011-11-04Not applicableUs
Isosorbidetablet20 mg/1oralHikma Pharmaceutical1983-04-26Not applicableUs
Isosorbidetablet5 mg/1oralGolden State Medical Supply, Inc.1987-10-26Not applicableUs
Isosorbidetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralREMEDYREPACK INC.2011-10-19Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralCardinal Health2013-10-15Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralbryant ranch prepack1978-12-01Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralKAISER FOUNDATION HOSPITALS2011-03-15Not applicableUs
Isosorbide Dinitratetablet2.5 mg/1sublingualWest ward Pharmaceutical Corp1978-12-01Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralSandoz Inc1988-01-07Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralAmerican Health Packaging2013-10-15Not applicableUs
Isosorbide Dinitratetablet30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-02-10Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralPar Pharmaceutical Inc.1981-12-15Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralWest Ward Pharmaceuticals Corp1983-04-26Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralMajor Pharmaceuticals1988-01-07Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralCarilion Materials Management1978-12-01Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralCardinal Health1988-01-07Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralKAISER FOUNDATION HOSPITALS2011-10-31Not applicableUs
Isosorbide Dinitratetablet30 mg/1oralPar Pharmaceutical Inc.1983-02-10Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralAvera Mc Kennan Hospital2015-04-15Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralCaraco Pharmaceutical Laboratories Ltd.2009-09-22Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1981-12-152016-01-27Us
Isosorbide Dinitratetablet5 mg/1sublingualWest ward Pharmaceutical Corp1978-12-01Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralSandoz Inc1988-04-07Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-07Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralREMEDYREPACK INC.2012-12-27Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralCardinal Health1988-01-07Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralMajor Pharmaceuticals1988-04-07Not applicableUs
Isosorbide Dinitratetablet30 mg/1oralCarilion Materials Management1983-02-10Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1978-12-01Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralPar Pharmaceutical Inc.1979-12-13Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1979-12-22Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralWest Ward Pharmaceuticals Corp1978-12-01Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralMajor Pharmaceuticals2004-02-03Not applicableUs
Isosorbide Dinitratetablet30 mg/1oralCarilion Materials Management1983-02-10Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralA S Medication Solutions Llc1988-04-07Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-04-07Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralREMEDYREPACK INC.2014-03-25Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1981-12-15Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralCardinal Health1988-04-07Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralbryant ranch prepack1978-12-01Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralKAISER FOUNDATION HOSPITALS2010-03-25Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralREMEDYREPACK INC.2011-03-10Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralCarilion Materials Management2009-09-22Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-04-26Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralPar Pharmaceutical Inc.1979-12-22Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralCore Pharma, Llc2008-04-022016-03-16Us
Isosorbide Dinitratetablet10 mg/1oralWest Ward Pharmaceuticals Corp1978-12-01Not applicableUs
Isosorbide Dinitratetablet20 mg/1oralMajor Pharmaceuticals2004-02-03Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralCarilion Materials Management1978-12-01Not applicableUs
Isosorbide Dinitratetablet, extended release40 mg/1oralPhysicians Total Care, Inc.1995-01-18Not applicableUs
Isosorbide Dinitratetablet5 mg/1oralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralREMEDYREPACK INC.2016-03-11Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralAmerican Health Packaging2013-10-15Not applicableUs
Isosorbide Dinitratetablet10 mg/1oralSandoz Inc1988-01-07Not applicableUs
Isosorbide Sublingualtablet2.5 mg/1sublingualGolden State Medical Supply, Inc.1978-12-01Not applicableUs
Isosorbide Sublingualtablet5 mg/1sublingualGolden State Medical Supply, Inc.1987-11-02Not applicableUs
Isosorrbide Dinitratetablet30 mg/1oralWest ward Pharmaceutical Corp2007-01-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarvasinAyerst
Dilatrate-SRSchwarz
FlindixVitória
IsoketSchwarz
IsorbidArmstrong
IsordilValeant
NitrosorbideLusofarmaco
SorbidilatActavis
Brand mixtures
NameLabellerIngredients
BidilArbor Pharmaceuticals
SaltsNot Available
Categories
UNIIIA7306519N
CAS number87-33-2
WeightAverage: 236.1363
Monoisotopic: 236.028065242
Chemical FormulaC6H8N2O8
InChI KeyInChIKey=MOYKHGMNXAOIAT-JGWLITMVSA-N
InChI
InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
IUPAC Name
(3S,3aS,6R,6aS)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][C@]12OC[[email protected]](O[N+]([O-])=O)[C@@]1([H])OC[[email protected]]2O[N+]([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurofurans
Sub ClassIsosorbides
Direct ParentIsosorbides
Alternative Parents
Substituents
  • Isosorbide
  • Alkyl nitrate
  • Oxolane
  • Organic nitrate
  • Nitrate ester
  • Organic nitro compound
  • Organic nitric acid or derivatives
  • Oxacycle
  • Organic 1,3-dipolar compound
  • Allyl-type 1,3-dipolar organic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organic zwitterion
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prevention of angina pectoris due to coronary artery disease.
PharmacodynamicsIsosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.
Mechanism of actionSimilar to other nitrites and organic nitrates, isosorbide dinitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
Related Articles
AbsorptionAbsorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.
Volume of distribution
  • 2 to 4 L/kg
Protein bindingVery low
Metabolism

Hepatic

Route of eliminationNot Available
Half life1 hour
ClearanceNot Available
ToxicitySymptoms of overdose include reduced cardiac output and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier+0.9559
Caco-2 permeable-0.5746
P-glycoprotein substrateNon-substrate0.8064
P-glycoprotein inhibitor INon-inhibitor0.6173
P-glycoprotein inhibitor IINon-inhibitor0.8911
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9057
CYP450 2D6 substrateNon-substrate0.9021
CYP450 3A4 substrateSubstrate0.5298
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9534
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9538
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7116
BiodegradationReady biodegradable0.7633
Rat acute toxicity2.4849 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5057
hERG inhibition (predictor II)Non-inhibitor0.9381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Schwarz pharma inc
  • Wyeth ayerst laboratories
  • Astrazeneca pharmaceuticals lp
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Biovail laboratories inc
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • West ward inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral
Tablet (extended-release)oral20 mg
Tablet (extended-release)oral40 mg
Capsuleoral40 mg/1
Capsule, extended releaseoral40 mg/1
Tabletsublingual5 mg
Tabletoral40 mg/1
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Tabletsublingual2.5 mg/1
Tabletsublingual5 mg/1
Tablet, extended releaseoral40 mg/1
Tabletoral30 mg
Tabletoral30 mg/1
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Isordil Titradose 40 mg tablet1.7USD tablet
Isordil 40 mg tablet1.58USD tablet
Dilatrate-sr 40 mg capsule1.48USD capsule
Isochron 40 mg tablet sa1.07USD tablet
Isosorbide Dinitrate CR 40 mg Controlled Release Tabs0.88USD tab
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Isordil Titradose 5 mg tablet0.68USD tablet
Isordil 5 mg tablet0.65USD tablet
Isosorbide dn 30 mg tablet0.53USD tablet
Isordil 10 mg tablet0.5USD tablet
Isosorbide Dinitrate 30 mg tablet0.5USD tablet
Cedocard-Sr 20 mg Sustained-Release Tablet0.44USD tablet
Isosorbide Dinitrate 10 mg tablet0.43USD tablet
Isosorbide Dinitrate 20 mg tablet0.43USD tablet
Isosorbide Dinitrate 2.5 mg Sublingual Tabs0.39USD tab
Isosorbide Dinitrate 5 mg Sublingual Tabs0.21USD tab
Isosorbide dn 2.5 mg tablet sl0.21USD tablet
Isosorbide dn 5 mg tablet sl0.21USD tablet
Isosorbide dn 20 mg tablet0.2USD tablet
Isosorbide Dinitrate 5 mg tablet0.17USD tablet
Isosorbide dn 10 mg tablet0.17USD tablet
Isosorbide dn 5 mg tablet0.17USD tablet
Apo-Isdn 30 mg Tablet0.09USD tablet
Apo-Isdn 5 mg Sublingual Tablet0.07USD tablet
Apo-Isdn 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463 No2000-09-082020-09-08Us
US6784177 No2000-09-082020-09-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point70 °CPhysProp
water solubility550 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.31HANSCH,C ET AL. (1995)
logS-2.63ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.938 mg/mLALOGPS
logP0.87ALOGPS
logP0.44ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area128.56 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity44.77 m3·mol-1ChemAxon
Polarizability18.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gunter Cordes, Ulrich Munch, Ewald Giesselmann, “Supersaturated isosorbide dinitrate solution, process for its production and its use.” U.S. Patent US4156736, issued August, 1976.

US4156736
General ReferencesNot Available
External Links
ATC CodesC01DA58C05AE02C01DA08
AHFS Codes
  • 24:12.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Isosorbide Dinitrate.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Dinitrate.
AmiodaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.
AmobarbitalAmobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Amyl NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Apraclonidine.
AprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.
AtazanavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate.
AtomoxetineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atomoxetine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Azilsartan medoxomil.
BarbitalBarbital may increase the hypotensive activities of Isosorbide Dinitrate.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Dinitrate.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Dinitrate.
BexaroteneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bexarotene.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.
BoceprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan.
BretyliumThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.
BumetanideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.
CanagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Dinitrate.
CaptoprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.
CarbamazepineThe metabolism of Isosorbide Dinitrate can be increased when combined with Carbamazepine.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.
CarvedilolThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carvedilol.
CeritinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ceritinib.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Dinitrate.
CilazaprilThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.
ClarithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.
ClotrimazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dabrafenib.
DapagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Dinitrate.
DarunavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate.
DiclofenamideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Diclofenamide.
DihydroergotamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Isosorbide Dinitrate.
DinutuximabThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dipyridamole.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.
DoxycyclineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone.
DuloxetineIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Efavirenz.
EmpagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Dinitrate.
EnzalutamideThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Dinitrate.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.
ErythromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Dinitrate.
Etacrynic acidThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.
EthanolEthanol may increase the vasodilatory activities of Isosorbide Dinitrate.
EtravirineThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Etravirine.
FelodipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.
FluconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.
FosphenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Fosphenytoin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.
Fusidic AcidThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Fusidic Acid.
GuanfacineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
HydralazineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.
IdelalisibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.
IndinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Indinavir.
IrbesartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.
IsavuconazoniumThe metabolism of Isosorbide Dinitrate can be decreased when combined with Isavuconazonium.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Dinitrate.
ItraconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ketoconazole.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.
LevobunololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levobunolol.
LevodopaIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Levodopa.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.
LopinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.
LovastatinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Luliconazole.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Isosorbide Dinitrate.
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Dinitrate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.
MethyldopaThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
MetipranololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Dinitrate.
MifepristoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Mifepristone.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Dinitrate.
MitotaneThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Dinitrate.
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Dinitrate.
NadololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.
NafcillinThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Nafcillin.
NebivololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.
NefazodoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nesiritide.
NetupitantThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Dinitrate.
NifedipineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nifedipine.
NilotinibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Dinitrate.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Dinitrate.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Dinitrate.
OlaparibThe metabolism of Isosorbide Dinitrate can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate.
OsimertinibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Osimertinib.
PalbociclibThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.
PapaverineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.
PenbutololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Dinitrate.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
PhenytoinThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenytoin.
PindololThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pindolol.
PosaconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Posaconazole.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Prilocaine.
PrimidonePrimidone may increase the hypotensive activities of Isosorbide Dinitrate.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.
QuetiapineThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Dinitrate.
RanolazineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ranolazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Dinitrate.
RifabutinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Isosorbide Dinitrate can be increased when combined with Rifapentine.
RiociguatIsosorbide Dinitrate may increase the hypotensive activities of Riociguat.
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Isosorbide Dinitrate.
RisperidoneIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ritonavir.
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rosiglitazone.
SaquinavirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
SildenafilSildenafil may increase the vasodilatory activities of Isosorbide Dinitrate.
SiltuximabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Simeprevir.
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sodium Nitrite.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate.
St. John's WortThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sulfisoxazole.
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Dinitrate.
TelaprevirThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Isosorbide Dinitrate can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.
TerazosinThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.
ThiamylalThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.
ThiopentalThiopental may increase the hypotensive activities of Isosorbide Dinitrate.
TiclopidineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Dinitrate.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.
TocilizumabThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Dinitrate.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.
UdenafilUdenafil may increase the vasodilatory activities of Isosorbide Dinitrate.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Dinitrate.
VenlafaxineThe metabolism of Isosorbide Dinitrate can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.
VoriconazoleThe metabolism of Isosorbide Dinitrate can be decreased when combined with Voriconazole.
ZiprasidoneThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.
Food Interactions
  • Take without regard to meals. Absorption is faster on an empty stomach.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein kinase activity
Specific Function:
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
Gene Name:
NPR1
Uniprot ID:
P16066
Molecular Weight:
118918.11 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Villarroya M, Lopez MG, de Pascual R, Garcia AG: Preclinical profile of PF9404C, a nitric oxide donor with beta receptor blocking properties. Cardiovasc Drug Rev. 2005 Summer;23(2):149-60. [PubMed:16007231 ]
  4. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu K, Takabayashi A, Adachi T, Semenza GL, Fukuda K: The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun. 2004 Nov 5;324(1):417-23. [PubMed:15465035 ]
  5. Beauregard C, Brandt PC, Chiou GC: Nitric oxide and cyclic GMP-mediated protein secretion from cultured lacrimal gland acinar cells. J Ocul Pharmacol Ther. 2002 Oct;18(5):429-43. [PubMed:12419094 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:25